(Q47217969)

11 January 2018

title

CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques (English)

1 reference

11 January 2018

author name string

Dennis M Klinman

1

1 reference

11 January 2018

Hang Xie

2

1 reference

11 January 2018

Stephen F Little

3

1 reference

11 January 2018

Debra Currie

4

1 reference

11 January 2018

Bruce E Ivins

5

1 reference

11 January 2018

language of work or name

English

0 references

publication date

1 July 2004

1 reference

11 January 2018

published in

Vaccine

1 reference

11 January 2018

volume

22

1 reference

11 January 2018

issue

21-22

1 reference

11 January 2018

page(s)

2881-2886

1 reference

11 January 2018

Bioterrorism: a clear and present danger

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Molecular pathogenesis of Bacillus anthracis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Anthrax vaccine: short-term safety experience in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

CpG oligodeoxynucleotides as vaccine adjuvants in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

CpG motifs in bacterial DNA trigger direct B-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

A Toll-like receptor recognizes bacterial DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Therapeutic applications of CpG-containing oligodeoxynucleotides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

DNA activates human immune cells through a CpG sequence-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Mechanism and function of a newly identified CpG DNA motif in human primary B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Combination of microneutralization and avidity assays: Improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

inferred from DOI database lookup

7 January 2021

based on heuristic

Estimation of the avidity of immunoglobulin G for routine diagnosis of chronic Toxoplasma gondii infection in pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Amplification of antibody production by phosphorothioate oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Type I interferon-mediated stimulation of T cells by CpG DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

10.1016/J.VACCINE.2003.12.020

7 January 2021

Identifiers

DOI

1 reference

11 January 2018

1 reference

11 January 2018